Robert J. Gould, Director at Fulcrum Therapeutics, Inc. (FULC), sold 188,502 shares at $24.02 ($4.6M) on 2022-04-04, disclosed to the SEC on 2022-04-05.
Open-market sale of $4.6M FULC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.03 | 34,464 | $828K | 18.2% |
| 2 | $24.03 | 34,464 | $828K | 18.2% |
| 3 | $24.02 | 7,235 | $174K | 3.8% |
| 4 | $24.02 | 7,235 | $174K | 3.8% |
| 5 | $24.26 | 52,552 | $1.3M | 28.0% |
| 6 | $24.26 | 52,552 |
| $1.3M |
| 28.0% |
| Total | $24.16 avg | 188,502 | $4.6M | 100% |
| Filing → |
| FULC | SELL | 2026-01-06 | $356K | — | Filing → |
| FULC | SELL | 2025-11-21 | $165K | — | Filing → |
| FULC | SELL | 2023-01-13 | $101K | — | Filing → |